|Session title||Fight falsified and substandard medicines in Africa|
|Coordinator||Harald Zimmer, Senior Manager International Affairs, vfa|
|Hosts||vfa.Research-Based Pharmaceutical Companies|
|Session objectives||-Description and fact-based analysis of the problem and the issues of the fight against falsified and substandard medicine
-Demonstration of different approaches to reduce falsified and substandard drugs entering the distribution chain with a focus on needs specific for African markets
-Illustrate the intense work and commitment of research-based pharmaceutical companies together with other stakeholders to detecting falsified and substandard products, e.g. by fostering the use of the Minilab and building a strong network around it
-Improved safety for patients can only be achieved by the sound operation of many stakeholders
|Session abstract||Falsified and substandard medicines are a global problem that endangers the health and lives of patients. The WHO estimates that about ten percent of all medicines in low- and middle-income countries are falsified or substandard, and in some regions the situation is even much worse. High-quality medicines are essential to protect patients and prevent treatment failure. Risk reduction measures focus on identifying and elimination of falsified and substandard medicines in pharmaceutical markets.
The purpose of this session is to first give an overview and to analyze the scope of the problem with a focus on Africa. Practical and locally appropriate options to reduce the risk of falsified and substandard medicine entering the market will then be identifies and discussed between different stakeholder groups from Africa and Europe.
|Session Format||Panel Discussion||Workshop 10||Plenary|
|Chairs||Chair: Prof. Dr. Lutz HEIDE from the University of Tuebingen, Germany|
|Dr. Jane Ruth ACENG, Minister of Health, Uganda (Policy/Government)||Uganda’s strategy to fight falsified and substandard medicines:Transnational cooperation against falsified and substandard medicines in Africa (e.g., Lomé Initiative)||Invited|
|Prof. Dr. Moji ADEJEJE, Director National Agency for Food and Drug Administration and Control, Nigeria (Policy/Government)||The role of national drug regulatory agencies in the fight against falsified and substandard medicines in Africa: Lessons learnt and recommendations for future priorities||Invited|
|Prof. Dr. Pierre Claver KAYUMBA, Associate Professor, University of Rwanda (Academia)||Falsified and substandard medicines in Africa: their prevalence, their detection, and prevention of their entry into the supply chain.
Insights and recommendations from the EAC Regional Centre of Excellence for Vaccines, Immunizations and Health Supply Chain Management at the University of Kigali, Rwanda
|Dr. Richard NECI CIZUNGU, Pharmacist, Managing Director – Depot Central Medico-Pharmaceutique, 8e CEPAC, Faith-based drug supply unit, Democratic Republic of Congo (Civil Society)||The Ecumenical Pharmaceutical Network and its activities in the fight against falsified and substandard medicines in Africa: Lessons learnt and recommendations for future action||Invited|
|Dr. Karim BENDHAOU, President, North West Africa group, Merck (Private sector)||Merck’s strategies and activities to prevent falsified and substandard medicines entering the supply chain:
The GPHF’s MINILAB – a mobile field laboratory to detect and verify falsified and substandard medicines
|N. N., vfa||Prevalence of falsified and substandard medicines in Europe:
Implementation of a verification system securing the legal supply chain across whole EuropeExperiences made, lessons learnt, options to transfer the system
|N.N., Interacademy Partnership (Optional)||Launch of a statement on “Furthering the fight against falsified and substandard medical products“.|
Event Timeslots (1)
ROOM 6 SHEEMA